BR112022024760A2 - Métodos de tratamento do complexo de esclerose tuberosa - Google Patents

Métodos de tratamento do complexo de esclerose tuberosa

Info

Publication number
BR112022024760A2
BR112022024760A2 BR112022024760A BR112022024760A BR112022024760A2 BR 112022024760 A2 BR112022024760 A2 BR 112022024760A2 BR 112022024760 A BR112022024760 A BR 112022024760A BR 112022024760 A BR112022024760 A BR 112022024760A BR 112022024760 A2 BR112022024760 A2 BR 112022024760A2
Authority
BR
Brazil
Prior art keywords
methods
tuberous sclerosis
treatment
sclerosis complex
individual
Prior art date
Application number
BR112022024760A
Other languages
English (en)
Inventor
Garibaldi George
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of BR112022024760A2 publication Critical patent/BR112022024760A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Fruits And Vegetables (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODOS DE TRATAMENTO DO COMPLEXO DE ESCLEROSE TUBEROSA. A presente invenção refere-se a métodos de tratamento do complexo de esclerose tuberosa em um indivíduo que precisa do mesmo ao administrar ao indivíduo composições que compreendem um modulador alostérico negativo (NAM) de mGlu5 que tem a estrutura de Fórmula (I).
BR112022024760A 2020-06-05 2021-06-04 Métodos de tratamento do complexo de esclerose tuberosa BR112022024760A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035313P 2020-06-05 2020-06-05
PCT/EP2021/065075 WO2021245281A1 (en) 2020-06-05 2021-06-04 Methods of treatment of tuberous sclerosis complex

Publications (1)

Publication Number Publication Date
BR112022024760A2 true BR112022024760A2 (pt) 2023-03-07

Family

ID=76325558

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024760A BR112022024760A2 (pt) 2020-06-05 2021-06-04 Métodos de tratamento do complexo de esclerose tuberosa

Country Status (12)

Country Link
US (2) US11684613B2 (pt)
EP (1) EP4161512A1 (pt)
JP (1) JP2023528895A (pt)
KR (1) KR20230027145A (pt)
CN (1) CN116056701A (pt)
AU (1) AU2021285273A1 (pt)
BR (1) BR112022024760A2 (pt)
CA (1) CA3180794A1 (pt)
CL (1) CL2022003435A1 (pt)
IL (1) IL298709A (pt)
MX (1) MX2022015407A (pt)
WO (1) WO2021245281A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
JP4690395B2 (ja) 2004-06-01 2011-06-01 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕ５レセプターアンタゴニストとしてのピリジン−４−エチニル−イミダゾール及びピラゾール
BRPI0720954A2 (pt) 2006-12-21 2014-03-18 Hoffmann La Roche Polimorfos de um antagonista de receptor mglur5
US8211882B2 (en) 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists

Also Published As

Publication number Publication date
US11684613B2 (en) 2023-06-27
EP4161512A1 (en) 2023-04-12
AU2021285273A1 (en) 2023-01-19
WO2021245281A1 (en) 2021-12-09
MX2022015407A (es) 2023-05-16
CL2022003435A1 (es) 2023-10-20
US20230100520A1 (en) 2023-03-30
US11998535B2 (en) 2024-06-04
KR20230027145A (ko) 2023-02-27
JP2023528895A (ja) 2023-07-06
US20230277513A1 (en) 2023-09-07
CA3180794A1 (en) 2021-12-09
CN116056701A (zh) 2023-05-02
IL298709A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
MX2018003161A (es) Metodos para tratar infecciones por virus arenaviridae y coronaviridae.
WO2018100558A8 (en) Cyclic dinucleotides as sting (stimulator of interferon genes) agonists
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112015022765A2 (pt) composição biocida e processo de tratamento da água ou de superfícies em contato com água
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CL2020003276A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
SG11201811536PA (en) Composition for removing sulfur-containing compound
BR112021018924A2 (pt) Derivado de heterocíclico pirrol, método de preparação do mesmo e aplicação do mesmo em medicamento
UA117673C2 (uk) Поліміксини, композиція, спосіб одержання і спосіб застосування (варіанти)
BR112022020291A2 (pt) Inibidores de cd38
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
EA201891808A1 (ru) Трис-амидные соединения и композиции, содержащие их
EA201991988A1 (ru) Композиции и способы для способствования росту волос с помощью ингибиторов mpc1
MX2021015673A (es) Alteracion de biopelicula.
ECSP22026478A (es) Inhibidor de diacilglicerol aciltransferasa 2
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112022024760A2 (pt) Métodos de tratamento do complexo de esclerose tuberosa
BR112016002643A2 (pt) composição para tratamento de pele e método para produção de uma composição para tratamento de pele
NI202100055A (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéutica del mismo.
BR112018007505A2 (pt) processo industrial para a preparação de sal de (e)-3-carboxiacrilato de (5s,10s)-10-benzil-16-metil-11,14,18-trioxo-15,17,19-trioxa-2,7,8-tritia-12-aza-henicosan-5-amínio
BR112018015044A2 (pt) formulação de cuidados pessoais, e método de umedecimento da pele ou dos cabelos em pacientes
BR112023001621A2 (pt) Métodos de tratamento de neuralgia trigeminal
RU2014123690A (ru) Терапевтическое средство при артрозе
BR112023022298A2 (pt) Moduladores de trex1